Abstract
Background: CS5931, a novel marine peptide, was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. However, its molecular targets have not been elucidated.
Methods: The target of the recombinant CS5931 was identified by pull-down/SDS-PAGE/MS approaches and confirmed by Western blot and surface plasmon resonance analysis. Transwell experiments were used to detect whether the recombinant CS5931 inhibited cancer migration and invasion via enolase 1. Dot blotting analysis was used to detect the effect of CS5931 on the interaction of enolase 1 and plasminogen, as well as enolase 1 and uPA/uPAR.
Results: Enolase 1 was identified as the molecular target interacting with the recombinant CS5931. Transwell experiment showed that the recombinant CS5931 was able to inhibit migration and invasion of HCT116 cells and enolase 1 overexpression reversed the effects of the recombinant CS5931 on migration and invasion of cancer cells. Dot blotting analysis revealed that the recombinant CS5931 interfered with the interaction among enolase 1 and plasminogen as well as enolase 1 and uPA/uPAR.
Conclusion: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and matastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent.
Keywords: Enolase1, migration and invasion, protein-protein interaction, recombinant CS5931.
Recent Patents on Anti-Cancer Drug Discovery
Title:CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1
Volume: 13 Issue: 3
Author(s): Shuonan Su, Huanli Xu, Xiaoliang Chen, Gan Qiao, Ammad A. Farooqi, Ye Tian, Ru Yuan, Xiaohui Liu, Cong Li, Xiao Li, Ning Wu and Xiukun Lin*
Affiliation:
- Department of Pharmacology, Capital Medical University, Beijing 100069,China
Keywords: Enolase1, migration and invasion, protein-protein interaction, recombinant CS5931.
Abstract: Background: CS5931, a novel marine peptide, was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. However, its molecular targets have not been elucidated.
Methods: The target of the recombinant CS5931 was identified by pull-down/SDS-PAGE/MS approaches and confirmed by Western blot and surface plasmon resonance analysis. Transwell experiments were used to detect whether the recombinant CS5931 inhibited cancer migration and invasion via enolase 1. Dot blotting analysis was used to detect the effect of CS5931 on the interaction of enolase 1 and plasminogen, as well as enolase 1 and uPA/uPAR.
Results: Enolase 1 was identified as the molecular target interacting with the recombinant CS5931. Transwell experiment showed that the recombinant CS5931 was able to inhibit migration and invasion of HCT116 cells and enolase 1 overexpression reversed the effects of the recombinant CS5931 on migration and invasion of cancer cells. Dot blotting analysis revealed that the recombinant CS5931 interfered with the interaction among enolase 1 and plasminogen as well as enolase 1 and uPA/uPAR.
Conclusion: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and matastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent.
Export Options
About this article
Cite this article as:
Su Shuonan , Xu Huanli , Chen Xiaoliang , Qiao Gan , Farooqi A. Ammad , Tian Ye , Yuan Ru , Liu Xiaohui , Li Cong , Li Xiao, Wu Ning and Lin Xiukun *, CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1, Recent Patents on Anti-Cancer Drug Discovery 2018; 13 (3) . https://dx.doi.org/10.2174/1574892813666180628170240
DOI https://dx.doi.org/10.2174/1574892813666180628170240 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance
Current Drug Metabolism Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Letters in Drug Design & Discovery Mesenchymal Stem Cell Therapy in Intracerebral Haemorrhagic Stroke
Current Medicinal Chemistry Hsp90 as Drug Target Against Bacterial and Fungal Infections
Current Chemical Biology Recent Advances in Optical Mammography
Current Medical Imaging Small Non-Coding RNAs as Biomarkers
Recent Patents on Biomarkers P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Medical Treatment Of Elderly Patients With Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design Insights into Airway Infections by Enterococci: A Review
Recent Patents on Anti-Infective Drug Discovery The Therapeutic Potential of miR-7 in Cancers
Mini-Reviews in Medicinal Chemistry